Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03941587
Recruitment Status : Not yet recruiting
First Posted : May 8, 2019
Last Update Posted : December 17, 2020
Sponsor:
Collaborators:
National University Hospital, Singapore
Tan Tock Seng Hospital
Information provided by (Responsible Party):
Gemmy Cheung Chui Ming, Singapore National Eye Centre

Brief Summary:
In this study, we aim to evaluate the efficacy and safety of an individualized dosing schedule comprising Aflibercept and RF-PDT in patients with polypoidal choroidal vasculopathy (PCV). The objective is to compare the visual improvement from baseline to month 12, in eyes with PCV treated with Aflibercept monotherapy versus combination of Aflibercept with reduced fluence photodynamic therapy (RF-PDT)

Condition or disease Intervention/treatment Phase
Polypoidal Choroidal Vasculopathy Drug: Aflibercept + reduced fluence photodynamic therapy (RF-PDT) Drug: Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT) Not Applicable

Detailed Description:

Age related macular degeneration (AMD) is one of the leading causes of blindness worldwide. In its exudative or wet form, choroidal neovascularization (CNV) causes an exudative maculopathy resulting in sudden loss of vision with severe effects on patients' quality of life. Intravitreal injections of anti-vascular endothelial growth factor agents (anti-VEGF) have become the mainstay of treatment for AMD CNV and has been shown to have favorable outcomes in most AMD CNV subtypes. In the Asian population, however, a particular subtype called polypoidal choroidal vasculopathy (PCV), which affects about 50% of exudative maculopathy, has been shown to have less favorable response to anti-VEGF therapy.

The best treatment option for PCV has remained unclear. Current best evidence is from 2 recent randomized controlled trials, the EVEREST II trial which compares the efficacy of ranibizumab with or without photodynamic therapy (PDT) for treatment of PCV and the PLANET trial which compares Aflibercept monotherapy against a rescue PDT when Aflibercept is deemed ineffective. Both trials have reported significant improvement in visual outcomes, however there remain significant unanswered questions and unmet needs regarding the use of Aflibercept and PDT as the best treatment for PCV.

In this study, we aim to compare the efficacy of combination Aflibercept with RF-PDT (at baseline) and Aflibercept monotherapy. This particular strategy has not been studies before and represents the amalgamation of unanswered questions from the best evidence to date for the treatment of PCV.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multi-center randomized, double-masked clinical trial.
Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-center Randomized Clinical Trial Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT for the Treatment of Polypoidal Choroidal Vasculopathy
Estimated Study Start Date : January 5, 2021
Estimated Primary Completion Date : December 30, 2021
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Aflibercept + RF-PDT

Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with Aflibercept (dosage=2mg/0.05ml) through an intravitreal injection + RF-PDT ( 6mg/m2 intravenous infusion of Verteporfin followed by laser light at a dose rate of 25 Joules/cm2) at baseline.

Aflibercept- 1st treatment (baseline) followed by minimum retreatment interval of 4 weeks (from Baseline to week 8) and then retreatment at intervals of 4 weeks pro re nata (PRN) retreatment( week 12-48). Primary endpoint at week 52.

RF-PDT treatment at baseline followed by pro re nata (PRN) at 12 week intervals.

At each visit, subjects will be assessed based on BCVA, ophthalmic examination and Optical Coherence Tomography (OCT)

Drug: Aflibercept + reduced fluence photodynamic therapy (RF-PDT)
Aflibercept dosage of 2mg in 0.05ml along with intravenous infusion of Verteporfin (6mg/m2)followed by laser light at a dosage of 25J/cm2
Other Names:
  • Eylea
  • Visudyne

Active Comparator: Aflibercept + sham RF-PDT

Patients with symptomatic macular PCV (n=80) as confirmed by Indocyanine green Angiography(ICGA) will be treated with Aflibercept (dosage=2mg/0.05ml) through an intravitreal injection, at baseline. A minimum of 1 injection(baseline) followed by minimum pro re nata (PRN) retreatment interval of 4 weeks ( from baseline to week 8) and then a minimum of 4 weeks retreatment thereafter (week 12-48). Primary endpoint at week 52.

Sham RF-PDT treatment at baseline followed by pro re nata (PRN) at 12 week intervals.

At each visit, subjects will be assessed based on Best Corrected Visual Acuity (BCVA), ophthalmic examination and Optical Coherence Tomography (OCT)

Drug: Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)
Aflibercept dosage of 2mg in 0.05ml along with sham photodynamic therapy
Other Name: Eylea




Primary Outcome Measures :
  1. Visual Acuity change [ Time Frame: 12 months ]
    Loss of ≥ 5 letters from Best Corrected Visual Acuity since baseline


Secondary Outcome Measures :
  1. Optical Coherence Tomography [ Time Frame: 12 months ]
    For evidence of intraretinal or subretinal fluid, ill-defined hyper-reflective material and/or new hemorrhage

  2. Optical Coherence Tomography-Angiograph [ Time Frame: 12 months ]
    For evidence of intraretinal or subretinal fluid, ill-defined hyper-reflective material and/or new hemorrhage

  3. Color Fundus photography [ Time Frame: baseline, month 3, month12 ]
    inspect anomalies associated to diseases that affect the eye, and to monitor their progression

  4. Autofluorescence Photography [ Time Frame: baseline, month 3, month12 ]
    Retinal imaging

  5. Fundus Fluorescein Angiography [ Time Frame: Baseline, month 3, month 12 ]
    Retinal circulation

  6. Intra Ocular Pressure (IOP) [ Time Frame: Baseline, 12 months ]
    Fluid Pressure in eye



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged over 50 years old at the time of informed consent.
  • Provide written informed consent.
  • Willingness and ability to comply with all scheduled visits and study procedures.
  • Confirmed diagnosis of symptomatic macular PCV based ICGA.
  • Activity of PCV confirmed by exudative activity involving the macula on OCT or Fluorescein Angiography (FA) or both.

    • Presence of intra retinal or subretinal fluid/blood at the fovea as seen on OCT
    • Treatment naïve

      • NO previous treatment with intravitreal anti-VEGF agents, regardless of the indication
      • NO previous thermal laser in the macular region, or verteporfin photodynamic therapy (vPDT), regardless of indication
      • NO other previous treatment for neovascular AMD (nAMD), except oral supplements and traditional Chinese medicine
  • An ETDRS BCVA of 4 to 73 letters (Snellen equivalent approximately 20/32 to 20/800) in the study eye.
  • Greatest Linear Dimension (GLD) of the total lesion area (BVN + polyps) <5400µm (~9 mucopolysaccharidoses (MPS) Disc Areas) as delineated by ICGA.

Exclusion Criteria: - Participant

  • Medical condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
  • Participation in an investigational trial within 30 days of enrollment which involves treatment with unapproved investigational drug.
  • Known allergy to any component of the study drug.
  • Blood pressure> 180/110 (systolic above 180 OR diastolic above 110 on repeated measurements). If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.
  • Myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization.
  • Systemic anti-VEGF or pro-VEGF treatment within four months prior to randomization or anticipated use during the study.
  • Amblyopia or blind in one eye Study Eye
  • Eye with intra retinal or sub-retinal fluid due to other causes than PCV
  • An ocular condition is present (other than PCV) that, in the opinion of the investigator, might affect intra or sub retinal fluid or alter visual acuity during the course of the study (e.g., Diabetic Macular Edema (DME), vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.)
  • Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by more than three lines (i.e., cataract would be reducing acuity to worse than 20/40 if eye was otherwise normal).
  • Any intraocular surgery within 3 months of enrollment
  • Treatment with intra vitreal corticosteroids
  • History of retinal detachment or surgery for retinal detachment
  • History of vitrectomy
  • History of macular hole
  • Evidence of vitreomacular traction that may preclude resolution of macular edema &gt; 4 disc areas of intra/sub retinal hemorrhage
  • Aphakia
  • Exam evidence of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis

Other Eye

  • Active intraocular inflammation
  • History of uveitis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03941587


Contacts
Layout table for location contacts
Contact: Gemmy Cheung Chui Ming 63227460 gemmy.cheung.c.m@singhealth.com.sg
Contact: Kelvin Teo Yi Chong

Locations
Layout table for location information
Singapore
Singapore National Eye Centre
Singapore, Singapore, 168751
National University Hospital
Singapore, Singapore
Tan Tock Seng Hospital
Singapore, Singapore
Sponsors and Collaborators
Singapore National Eye Centre
National University Hospital, Singapore
Tan Tock Seng Hospital
Investigators
Layout table for investigator information
Principal Investigator: Gemmy Cheung Chui Ming Singapore National Eye Centre
Layout table for additonal information
Responsible Party: Gemmy Cheung Chui Ming, Professor, Singapore National Eye Centre
ClinicalTrials.gov Identifier: NCT03941587    
Other Study ID Numbers: R1735/58/2020
First Posted: May 8, 2019    Key Record Dates
Last Update Posted: December 17, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Verteporfin
Photosensitizing Agents
Dermatologic Agents